Phase II Randomized Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis

Trial Profile

Phase II Randomized Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2018

At a glance

  • Drugs Dexamethasone (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Olanzapine (Primary) ; Ondansetron (Primary) ; Aprepitant
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Acronyms OlaCINV
  • Most Recent Events

    • 02 Jul 2018 Planned primary completion date changed from 14 Mar 2019 to 25 May 2019.
    • 29 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top